Scinus Group Raises €3 Million for Cell Therapy Automation
Utrecht-based biotech innovator Scinus Group has secured €3 million in fresh funding to accelerate the scaling of its automated cell therapy platform. The capital injection will support industrialisation, regulatory advancement and commercial rollout of technologies designed to make advanced therapies more efficient, consistent and affordable.
Advancing Automated Cell Manufacturing
Scinus Group focuses on automating critical steps in the production of cell-based therapies, an area traditionally reliant on manual, labour-intensive processes. Its platform aims to streamline the cultivation, monitoring and processing of therapeutic cells, reducing variability and enabling higher throughput for hospitals and pharmaceutical partners.
The new funding will be used to refine the company’s bioreactor systems, enhance integrated process analytics and expand capabilities for Good Manufacturing Practice (GMP)-compliant production. By embedding advanced automation and data-driven process control, the company seeks to support the broader adoption of complex treatments such as CAR-T therapies and regenerative medicine products.
Strategic Positioning in Europe’s BioTech Ecosystem
Based in the Netherlands’ thriving life sciences corridor, Scinus Group is positioning itself as a key enabler in the European BioTech and HealthTech landscape. The company plans to deepen collaborations with clinical centres and industry partners that are struggling to scale from early-stage clinical trials to commercial manufacturing.
Industry observers note that demand for scalable cell therapy manufacturing solutions is rising sharply as more personalised and regenerative treatments advance through clinical pipelines. By focusing on automation and standardisation, Scinus Group aims to reduce production costs, shorten time-to-patient and support broader access to next-generation therapies.
The €3 million round underscores growing investor confidence in enabling technologies that address one of the biggest bottlenecks in advanced therapeutics: how to reliably manufacture complex cell products at scale while meeting stringent regulatory standards.